Rituximab in the treatment of acquired factor VIII inhibitors

Thrombosis and Haemostasis

Volumn 96, Issue 1, 2006, Pages 84-87

  Onitilo, Adedayo A ^a   Skorupa, Amy ^b   Lal, Asheesh ^d   Ronish, Elizabeth ^c   Mercier, Richard J ^e   Islam, Rezwan ^a   Lazarchick, John ^c  

^a Marshfield Clinic Weston Center   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Lexington Medical Center   (United States)

^e MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; SEPSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; AUTOANTIBODIES; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; THROMBOSIS;

EID: 33746675607     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH-06-03-0183     Document Type: Article

References (13)

1. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
2. Michiels JJ. Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment. Clin Appl Thromb Hemost 2000; 6: 82-6.
3. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-3.
4. Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70: 753-7.
5. Schulman S, Langevitz P, Livneh A, et al. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1996; 76: 344-6.
6. Sultan Y, Kazatchkine MD, Maisonneuve P, et al. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765-8.
7. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-81.
8. Wiestner A, Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
9. Stasi R, Brunetti M, Stipa E, et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
10. Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002; 119: 578.
11. Mathias M, Khair K, Hann I, et al. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-8.
12. Aggarwal A, Grewal R, Green RJ, et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia 2005; 11: 13-9.
13. Rosendaal FR. High levels of factor VIII and venous thrombosis. Thromb Haemost 2000; 83: 1-2.